Opthea’s Wet AMD Program Featured at Ophthalmology Events

Rhea-AI Summary

Opthea (ASX/NASDAQ: OPT) announced its participation in two major ophthalmology conferences where sozinibercept will be featured. At the 17th Congress of APVRS, Dr. Gregg T. Kokame will present Phase 2b trial data showing that patients with polypoidal choroidal vasculopathy treated with a combination of sozinibercept and ranibizumab achieved significantly better visual and anatomic outcomes compared to ranibizumab alone at 24 weeks. Additionally, CEO Frederic Guerard will present at the Ophthalmology Innovation Summit XIV during the Retina Innovation Showcase.

Positive

• Phase 2b trial data demonstrates significantly better outcomes for combination therapy versus standard treatment
• Positive clinical results in polypoidal choroidal vasculopathy (PCV) subgroup

Negative

• None.

17 Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024

Ophthalmology Innovation Summit XIV, November 23, 2024

MELBOURNE, Australia, and PRINCETON, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Opthea and sozinibercept will be highlighted during two upcoming Ophthalmology conferences.

Conference details are as follows:

The 17^th Congress of the Asia-Pacific Vitreo-Retina Society (APVRS)

Session:		Rapid Fire 4 – Retina (Medical & Surgical)
Timing:		Friday, November 22, 2024, 3:15 – 3:20 PM Singapore time (GMT+8)
Presentation:		Intravitreal Sozinibercept (anti-VEGF-C/-D ‘trap’) Combined with Ranibizumab for the Treatment of Polypoidal Choroidal Vasculopathy: A Predefined Phase 2b Subgroup Analysis
Presenter:		Gregg T. Kokame, MD, MMM, FASRS
Abstract:		https://2024.apvrs.org/abstract/?code=200963

Gregg T. Kokame, MD, MMM, FASRS, will present data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured at 24 weeks. Data from this subgroup show that patients treated with a combination of sozinibercept and ranibizumab experienced significantly better visual and anatomic outcomes compared to ranibizumab alone.

APVRS, themed Transforming Retinal Disease Management with Technology, gathers a distinguished international faculty of top specialists in vitreo-retina to share their expertise and experience. The scientific program will focus on exciting areas such as novel surgical innovations
and therapies, and latest advances in imaging and research.

Ophthalmology Innovation Summit XIV (OIS)

Session:		Retina Innovation Showcase
Timing:		Saturday, November 23, 2024, 11:15 AM – 12:50 PM PT
Presenter:		Frederic Guerard, PharmD, CEO, Opthea
Agenda:		https://ois.net/ois-xiv-agenda/

The Ophthalmology Innovation Summit connects clinical, corporate, and capital leaders to drive the ophthalmic market forward. It showcases groundbreaking advancements and clinical insights in both anterior and posterior ophthalmology segments and offers the opportunity to learn, network and collaborate.

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.

Authorized for release to ASX by Frederic Guerard, PharmD, CEO

Investor Inquiries

PJ Kelleher 
LifeSci Advisors, LLC 
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579 

Media Inquiries 

Silvana Guerci-Lena 
NorthStream Global Partners 
Email: silvana@nsgpllc.com 

Join our email database to receive program updates:  
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com   

Source: Opthea Limited

FAQ

What were the results of Opthea's (OPT) Phase 2b trial for sozinibercept in PCV patients?

The Phase 2b trial showed that patients treated with sozinibercept combined with ranibizumab achieved significantly better visual and anatomic outcomes compared to ranibizumab alone at 24 weeks.

When will Opthea (OPT) present its sozinibercept data at APVRS 2024?

Opthea will present the sozinibercept data at APVRS on Friday, November 22, 2024, from 3:15 – 3:20 PM Singapore time.

Where will Opthea (OPT) showcase its wet AMD program in November 2024?

Opthea will showcase its program at two events: the 17th Congress of APVRS (November 22-24) and the Ophthalmology Innovation Summit XIV (November 23).